AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
阿斯利康斥资12亿美元收购石药集团长效减肥药权益

AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies.
阿斯利康正以与石药集团达成的一笔12亿美元预付款协议兑现其对manbetx3.0 150亿美元的承诺，该合作涵盖八项药物研发项目和多种平台技术。